Reports Q4 revenue $307M, consensus $300.01M. “We delivered solid financial results for Q4 2024, including returning to year-over-year revenue ...

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Omnicell (OMCL – Research Report). The company’s shares ...

Omnicell OMCL is advancing toward the industry-defined vision of Autonomous Pharmacy by leveraging automation and advanced services across its cloud-based platform. The strength of the company’s ...

Get prepared with the key expectations. Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article. Zacks Medical Info Systems industry stocks like Enovis, Omnicell and ...